How Big Will the SpaceX IPO Be?
Operated up to now as a private business, SpaceX will…
Buy
56
ALKS Quote, Financials, Valuation and Earnings
Last price:
$35.10
Seasonality move
:
-5.29%
Day range:
$33.55 - $34.40
52-week range:
$25.17 - $36.45
Dividend yield:
0%
P/E ratio:
16.77x
P/S ratio:
3.74x
P/B ratio:
3.23x
Volume:
1.7M
Avg. volume:
2M
1-year change:
8.48%
Market cap:
$5.6B
Revenue:
$1.6B
EPS (TTM):
$2.02
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ALKS
Alkermes Plc
|
$380.3M | $0.44 | 19.99% | 90.33% | $43.75 |
|
AVDL
Avadel Pharmaceuticals Plc
|
$80.3M | $0.18 | 48.83% | -76.67% | $20.94 |
|
CRMD
CorMedix, Inc.
|
$127M | $0.80 | 195.3% | 90.44% | $14.86 |
|
FOLD
Amicus Therapeutics, Inc.
|
$185M | $0.16 | 29.62% | 234.42% | $14.50 |
|
JAZZ
Jazz Pharmaceuticals Plc
|
$1.2B | $6.41 | 11.76% | 106.4% | $216.44 |
|
KRYS
Krystal Biotech, Inc.
|
$106.8M | $1.61 | 35.17% | 42.95% | $276.60 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ALKS
Alkermes Plc
|
$33.90 | $43.75 | $5.6B | 16.77x | $0.00 | 0% | 3.74x |
|
AVDL
Avadel Pharmaceuticals Plc
|
$21.54 | $20.94 | $2.1B | 299.90x | $0.00 | 0% | 8.52x |
|
CRMD
CorMedix, Inc.
|
$7.75 | $14.86 | $610.6M | 3.77x | $0.00 | 0% | 2.61x |
|
FOLD
Amicus Therapeutics, Inc.
|
$14.28 | $14.50 | $4.4B | -- | $0.00 | 0% | 7.31x |
|
JAZZ
Jazz Pharmaceuticals Plc
|
$165.41 | $216.44 | $10.1B | 15.09x | $0.00 | 0% | 2.43x |
|
KRYS
Krystal Biotech, Inc.
|
$272.91 | $276.60 | $7.9B | 40.93x | $0.00 | 0% | 21.82x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ALKS
Alkermes Plc
|
3.97% | 0.645 | 1.45% | 3.09x |
|
AVDL
Avadel Pharmaceuticals Plc
|
27.56% | -0.013 | 2.52% | 2.14x |
|
CRMD
CorMedix, Inc.
|
1.16% | 2.954 | 0.48% | 1.60x |
|
FOLD
Amicus Therapeutics, Inc.
|
65.77% | -0.323 | 18.22% | 1.91x |
|
JAZZ
Jazz Pharmaceuticals Plc
|
57.83% | 0.175 | 67.81% | 1.24x |
|
KRYS
Krystal Biotech, Inc.
|
0.83% | -0.755 | 0.19% | 9.43x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ALKS
Alkermes Plc
|
$341.2M | $89.1M | 20.4% | 22.16% | 22.6% | $84.4M |
|
AVDL
Avadel Pharmaceuticals Plc
|
$80.5M | $1.9M | -0.23% | -0.34% | 2.5% | $23.2M |
|
CRMD
CorMedix, Inc.
|
$93.1M | $51.3M | 94.54% | 95.25% | 49.24% | $30.4M |
|
FOLD
Amicus Therapeutics, Inc.
|
$147.7M | $34.3M | -2.18% | -7.02% | 20.27% | $35.3M |
|
JAZZ
Jazz Pharmaceuticals Plc
|
$828.9M | $161.5M | -3.78% | -9.16% | 14.34% | $429.4M |
|
KRYS
Krystal Biotech, Inc.
|
$92.1M | $41.4M | 19.74% | 19.91% | 42.31% | $38M |
Alkermes Plc vs. Competitors
-
Which has Higher Returns ALKS or AVDL?
Avadel Pharmaceuticals Plc has a net margin of 21% compared to Alkermes Plc's net margin of 0.03%. Alkermes Plc's return on equity of 22.16% beat Avadel Pharmaceuticals Plc's return on equity of -0.34%.
Company Gross Margin Earnings Per Share Invested Capital ALKSAlkermes Plc86.56% $0.49 $1.8B AVDLAvadel Pharmaceuticals Plc90.66% $0.00 $135.6M -
What do Analysts Say About ALKS or AVDL?
Alkermes Plc has a consensus price target of $43.75, signalling upside risk potential of 29.06%. On the other hand Avadel Pharmaceuticals Plc has an analysts' consensus of $20.94 which suggests that it could fall by -2.8%. Given that Alkermes Plc has higher upside potential than Avadel Pharmaceuticals Plc, analysts believe Alkermes Plc is more attractive than Avadel Pharmaceuticals Plc.
Company Buy Ratings Hold Ratings Sell Ratings ALKSAlkermes Plc11 3 0 AVDLAvadel Pharmaceuticals Plc0 10 0 -
Is ALKS or AVDL More Risky?
Alkermes Plc has a beta of 0.440, which suggesting that the stock is 56.009% less volatile than S&P 500. In comparison Avadel Pharmaceuticals Plc has a beta of 1.299, suggesting its more volatile than the S&P 500 by 29.901%.
-
Which is a Better Dividend Stock ALKS or AVDL?
Alkermes Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Avadel Pharmaceuticals Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alkermes Plc pays -- of its earnings as a dividend. Avadel Pharmaceuticals Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ALKS or AVDL?
Alkermes Plc quarterly revenues are $394.2M, which are larger than Avadel Pharmaceuticals Plc quarterly revenues of $77.5M. Alkermes Plc's net income of $82.8M is higher than Avadel Pharmaceuticals Plc's net income of $20K. Notably, Alkermes Plc's price-to-earnings ratio is 16.77x while Avadel Pharmaceuticals Plc's PE ratio is 299.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alkermes Plc is 3.74x versus 8.52x for Avadel Pharmaceuticals Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ALKSAlkermes Plc3.74x 16.77x $394.2M $82.8M AVDLAvadel Pharmaceuticals Plc8.52x 299.90x $77.5M $20K
-
Which has Higher Returns ALKS or CRMD?
CorMedix, Inc. has a net margin of 21% compared to Alkermes Plc's net margin of 49.9%. Alkermes Plc's return on equity of 22.16% beat CorMedix, Inc.'s return on equity of 95.25%.
Company Gross Margin Earnings Per Share Invested Capital ALKSAlkermes Plc86.56% $0.49 $1.8B CRMDCorMedix, Inc.89.26% $1.26 $378.5M -
What do Analysts Say About ALKS or CRMD?
Alkermes Plc has a consensus price target of $43.75, signalling upside risk potential of 29.06%. On the other hand CorMedix, Inc. has an analysts' consensus of $14.86 which suggests that it could grow by 91.71%. Given that CorMedix, Inc. has higher upside potential than Alkermes Plc, analysts believe CorMedix, Inc. is more attractive than Alkermes Plc.
Company Buy Ratings Hold Ratings Sell Ratings ALKSAlkermes Plc11 3 0 CRMDCorMedix, Inc.4 0 0 -
Is ALKS or CRMD More Risky?
Alkermes Plc has a beta of 0.440, which suggesting that the stock is 56.009% less volatile than S&P 500. In comparison CorMedix, Inc. has a beta of 1.358, suggesting its more volatile than the S&P 500 by 35.753%.
-
Which is a Better Dividend Stock ALKS or CRMD?
Alkermes Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CorMedix, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alkermes Plc pays -- of its earnings as a dividend. CorMedix, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ALKS or CRMD?
Alkermes Plc quarterly revenues are $394.2M, which are larger than CorMedix, Inc. quarterly revenues of $104.3M. Alkermes Plc's net income of $82.8M is lower than CorMedix, Inc.'s net income of $108.6M. Notably, Alkermes Plc's price-to-earnings ratio is 16.77x while CorMedix, Inc.'s PE ratio is 3.77x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alkermes Plc is 3.74x versus 2.61x for CorMedix, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ALKSAlkermes Plc3.74x 16.77x $394.2M $82.8M CRMDCorMedix, Inc.2.61x 3.77x $104.3M $108.6M
-
Which has Higher Returns ALKS or FOLD?
Amicus Therapeutics, Inc. has a net margin of 21% compared to Alkermes Plc's net margin of 10.24%. Alkermes Plc's return on equity of 22.16% beat Amicus Therapeutics, Inc.'s return on equity of -7.02%.
Company Gross Margin Earnings Per Share Invested Capital ALKSAlkermes Plc86.56% $0.49 $1.8B FOLDAmicus Therapeutics, Inc.87.38% $0.06 $673.2M -
What do Analysts Say About ALKS or FOLD?
Alkermes Plc has a consensus price target of $43.75, signalling upside risk potential of 29.06%. On the other hand Amicus Therapeutics, Inc. has an analysts' consensus of $14.50 which suggests that it could grow by 1.54%. Given that Alkermes Plc has higher upside potential than Amicus Therapeutics, Inc., analysts believe Alkermes Plc is more attractive than Amicus Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ALKSAlkermes Plc11 3 0 FOLDAmicus Therapeutics, Inc.0 7 0 -
Is ALKS or FOLD More Risky?
Alkermes Plc has a beta of 0.440, which suggesting that the stock is 56.009% less volatile than S&P 500. In comparison Amicus Therapeutics, Inc. has a beta of 0.417, suggesting its less volatile than the S&P 500 by 58.311%.
-
Which is a Better Dividend Stock ALKS or FOLD?
Alkermes Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alkermes Plc pays -- of its earnings as a dividend. Amicus Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ALKS or FOLD?
Alkermes Plc quarterly revenues are $394.2M, which are larger than Amicus Therapeutics, Inc. quarterly revenues of $169.1M. Alkermes Plc's net income of $82.8M is higher than Amicus Therapeutics, Inc.'s net income of $17.3M. Notably, Alkermes Plc's price-to-earnings ratio is 16.77x while Amicus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alkermes Plc is 3.74x versus 7.31x for Amicus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ALKSAlkermes Plc3.74x 16.77x $394.2M $82.8M FOLDAmicus Therapeutics, Inc.7.31x -- $169.1M $17.3M
-
Which has Higher Returns ALKS or JAZZ?
Jazz Pharmaceuticals Plc has a net margin of 21% compared to Alkermes Plc's net margin of 22.33%. Alkermes Plc's return on equity of 22.16% beat Jazz Pharmaceuticals Plc's return on equity of -9.16%.
Company Gross Margin Earnings Per Share Invested Capital ALKSAlkermes Plc86.56% $0.49 $1.8B JAZZJazz Pharmaceuticals Plc73.6% $4.08 $9.4B -
What do Analysts Say About ALKS or JAZZ?
Alkermes Plc has a consensus price target of $43.75, signalling upside risk potential of 29.06%. On the other hand Jazz Pharmaceuticals Plc has an analysts' consensus of $216.44 which suggests that it could grow by 30.85%. Given that Jazz Pharmaceuticals Plc has higher upside potential than Alkermes Plc, analysts believe Jazz Pharmaceuticals Plc is more attractive than Alkermes Plc.
Company Buy Ratings Hold Ratings Sell Ratings ALKSAlkermes Plc11 3 0 JAZZJazz Pharmaceuticals Plc9 1 0 -
Is ALKS or JAZZ More Risky?
Alkermes Plc has a beta of 0.440, which suggesting that the stock is 56.009% less volatile than S&P 500. In comparison Jazz Pharmaceuticals Plc has a beta of 0.272, suggesting its less volatile than the S&P 500 by 72.796%.
-
Which is a Better Dividend Stock ALKS or JAZZ?
Alkermes Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Jazz Pharmaceuticals Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alkermes Plc pays -- of its earnings as a dividend. Jazz Pharmaceuticals Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ALKS or JAZZ?
Alkermes Plc quarterly revenues are $394.2M, which are smaller than Jazz Pharmaceuticals Plc quarterly revenues of $1.1B. Alkermes Plc's net income of $82.8M is lower than Jazz Pharmaceuticals Plc's net income of $251.4M. Notably, Alkermes Plc's price-to-earnings ratio is 16.77x while Jazz Pharmaceuticals Plc's PE ratio is 15.09x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alkermes Plc is 3.74x versus 2.43x for Jazz Pharmaceuticals Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ALKSAlkermes Plc3.74x 16.77x $394.2M $82.8M JAZZJazz Pharmaceuticals Plc2.43x 15.09x $1.1B $251.4M
-
Which has Higher Returns ALKS or KRYS?
Krystal Biotech, Inc. has a net margin of 21% compared to Alkermes Plc's net margin of 81.15%. Alkermes Plc's return on equity of 22.16% beat Krystal Biotech, Inc.'s return on equity of 19.91%.
Company Gross Margin Earnings Per Share Invested Capital ALKSAlkermes Plc86.56% $0.49 $1.8B KRYSKrystal Biotech, Inc.94.21% $2.66 $1.1B -
What do Analysts Say About ALKS or KRYS?
Alkermes Plc has a consensus price target of $43.75, signalling upside risk potential of 29.06%. On the other hand Krystal Biotech, Inc. has an analysts' consensus of $276.60 which suggests that it could grow by 1.35%. Given that Alkermes Plc has higher upside potential than Krystal Biotech, Inc., analysts believe Alkermes Plc is more attractive than Krystal Biotech, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ALKSAlkermes Plc11 3 0 KRYSKrystal Biotech, Inc.11 0 0 -
Is ALKS or KRYS More Risky?
Alkermes Plc has a beta of 0.440, which suggesting that the stock is 56.009% less volatile than S&P 500. In comparison Krystal Biotech, Inc. has a beta of 0.463, suggesting its less volatile than the S&P 500 by 53.705%.
-
Which is a Better Dividend Stock ALKS or KRYS?
Alkermes Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Krystal Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alkermes Plc pays -- of its earnings as a dividend. Krystal Biotech, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ALKS or KRYS?
Alkermes Plc quarterly revenues are $394.2M, which are larger than Krystal Biotech, Inc. quarterly revenues of $97.8M. Alkermes Plc's net income of $82.8M is higher than Krystal Biotech, Inc.'s net income of $79.4M. Notably, Alkermes Plc's price-to-earnings ratio is 16.77x while Krystal Biotech, Inc.'s PE ratio is 40.93x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alkermes Plc is 3.74x versus 21.82x for Krystal Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ALKSAlkermes Plc3.74x 16.77x $394.2M $82.8M KRYSKrystal Biotech, Inc.21.82x 40.93x $97.8M $79.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will ISRG Stock Be in 5 Years?
Intuitive Surgical (NASDAQ:ISRG) is the innovative medical tech business behind…
Is Kratos Stock a Good Investment?
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.7T
P/E Ratio: 65x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Sell
48
Is GOOGL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Alerts
Buy
82
STX alert for Jan 29
Seagate Technology Holdings Plc [STX] is up 0.39% over the past day.
Buy
71
CLS alert for Jan 29
Celestica, Inc. [CLS] is down 15.13% over the past day.
Buy
58
AAOI alert for Jan 29
Applied Optoelectronics, Inc. [AAOI] is down 13.42% over the past day.
